Table 4.

	Regimen	Evaluable patients	CR, %	VGPR, %	PR, %	OR, %	PFS	OS
Current study	Bortez	39	0	10	41	51	1 yr 36% 2 yr 16%	1 yr 88% 2 yr 76% 3 yr 60%
Richardson 200914	Bortez	64	3	14	23	51	1 yr ~60% 2 yr ~25%	1 yr ~94% 2 yr ~89%
Jagannath 200511	Bortez+/-dex	32	3*/6†	9*/19†	28*/63†	40*/88†	NR	1 yr 87%
Harousseau 200612	Bortez-Dex	48	21	10	35	66	NR	NR
Rosinol 200713	Bortez alt Dex	40	12	7.5	40	60	NR	NR
Orlowski 200618	Doxil/bortez	57	16	NR	42	58	NR	NR
Popat ASH 200519	LD-PAD	20	11	31	47	89	2 yr	1 yr 73%
Oakavee 200519, 20	PAD	21	24	38	33	95	29 mo	1 yr 95%
Barlogie 200721	VDT-PACE	303	52	24	13	89	2 yr EFS 84%	2 yr 87%
San Miguel 200822, 26	MP-bortez	344	33	8	33	74	TTP 24 mo	1 yr ~90% 3-yr OS 68%

Bortez, bortezomib; dex, dexamethasone; LD-PAD, low dose bortezomib, doxorubicin, and dexamethasone; MP, melphalan and prednisone; VDT-PACE, bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide, NR, not reported.

^*2 cycles of single agent bortezomib

^†Overall response with dexamethasone added either after 2 cycles or after 4 cycles in 22 of the 32 patients.